Full-Length GCGR Protein: A Promising Therapy Target

Type 2 diabetes mellitus (T2DM) is the most common form of diabetes mellitus, and its prevalence has increased rapidly in recent decades. Studies have identified the Glucagon Receptor (GCGR) as an important drug target for the treatment of T2DM because blocking GCGR activation is an effective way to control abnormal hepatic glucose production in T2DM patients.

Schematic diagram of classic GCGR full-length protein

ACROBiosystems has launched a full-length GCGR protein（Cat. No. GCR-H52P5）by the “FLAG” VLP technology platform for developing multi-pass transmembrane target proteins. The GCGR protein has an interval of Ala 26-Asn 432 to confirm natural conformation to meet drug discovery scenarios and facilitate the development of drugs and therapies targeting GCGR.

Antibody Binding Verification Data

Immobilized Human GCGR Full Length Protein (VLP) (Cat. No. GCR-H52P5) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human GCGR antibody, Human IgG4 (Crotedumab) with a linear range of 0.1-20 ng/mL (QC tested).

Immobilized Human GCGR Full Length Protein (VLP) (Cat. No. GCR-H52P5) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human GCGR antibody, Human IgG2 (Volagidemab) with a linear range of 0.1-20 ng/mL (Routinely tested).

Request for Protocol

In addition, ACROBiosystems has also developed a series of high-quality GLP-1R recombinant proteins and functional cell lines for drug characterization, screening, and quality control, to meet the needs of multi-target drug discovery and development in obesity and diabetes.